{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:07:01Z","timestamp":1790482021367,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Vanessa McGuigan HMRI Fellowship in Ovarian Cancer"},{"name":"Medical Research Future Fund"},{"DOI":"10.13039\/100008018","name":"Victorian Cancer Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Data"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Low grade serous carcinoma (LGSOC) is a rare epithelial ovarian cancer with unique molecular characteristics compared to the more common tubo-ovarian high-grade serous ovarian carcinoma. Pivotal clinical trials guiding the management of epithelial ovarian cancer lack sufficient cases of LGSOC for meaningful subgroup analysis, hence overall findings cannot be extrapolated to rarer chemo-resistant subtypes such as LGSOC. Furthermore, there is a need for more effective therapies for the treatment of relapsed disease, as treatment options are limited. To address this, we conducted the largest quantitative high-throughput drug screening effort (n\u2009=\u20093436 compounds) in 12 patient-derived LGSOC cell lines and one normal ovary cell line to identify unexplored therapeutic avenues. Using a combination of high-throughput robotics, high-content imaging and novel data analysis pipelines, our data set identified 60 high and 19 moderate confidence hits which induced cancer cell specific cytotoxicity at the lowest compound dose assessed (0.1\u2009\u00b5M). We also revealed a series of known (<jats:italic>mTOR\/PI3K\/AKT)<\/jats:italic> and novel (<jats:italic>EGFR<\/jats:italic> and <jats:italic>MDM2-p53<\/jats:italic>) drug classes in which LGSOC cell lines showed demonstrable susceptibility to.<\/jats:p>","DOI":"10.1038\/s41597-024-03869-x","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T12:02:07Z","timestamp":1726747327000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma"],"prefix":"10.1038","volume":"11","author":[{"given":"Kathleen I.","family":"Pishas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla J.","family":"Cowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Llaurado-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennii","family":"Luu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Vary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola A.","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7773-4155","authenticated-orcid":false,"given":"Ian G.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaylene J.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dane","family":"Cheasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"3869_CR1","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/CCO.0000000000000216","volume":"27","author":"AJ Oswald","year":"2015","unstructured":"Oswald, A. J. & Gourley, C. Low-grade epithelial ovarian cancer: a number of distinct clinical entities? Curr Opin Oncol 27, 412\u2013419 (2015).","journal-title":"Curr Opin Oncol"},{"key":"3869_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","volume":"114","author":"DM Gershenson","year":"2009","unstructured":"Gershenson, D. M. et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 114, 48\u201352 (2009).","journal-title":"Gynecol Oncol"},{"key":"3869_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/PGP.0b013e31827630eb","volume":"32","author":"RH Ali","year":"2013","unstructured":"Ali, R. H., Kalloger, S. E., Santos, J. L., Swenerton, K. D. & Gilks, C. B. Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry. Int J Gynecol Pathol 32, 529\u2013535 (2013).","journal-title":"Int J Gynecol Pathol"},{"key":"3869_CR4","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1200\/JCO.2015.61.0873","volume":"33","author":"DM Gershenson","year":"2015","unstructured":"Gershenson, D. M. et al. Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. J Clin Oncol 33, 2675\u20132682 (2015).","journal-title":"J Clin Oncol"},{"key":"3869_CR5","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","volume":"35","author":"DM Gershenson","year":"2017","unstructured":"Gershenson, D. M. et al. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J Clin Oncol 35, 1103\u20131111 (2017).","journal-title":"J Clin Oncol"},{"key":"3869_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ygyno.2019.11.029","volume":"157","author":"M Llaurado Fernandez","year":"2020","unstructured":"Llaurado Fernandez, M. et al. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma. Gynecol Oncol 157, 12\u201320 (2020).","journal-title":"Gynecol Oncol"},{"key":"3869_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ygyno.2012.02.037","volume":"125","author":"DM Gershenson","year":"2012","unstructured":"Gershenson, D. M. et al. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 125, 661\u2013666 (2012).","journal-title":"Gynecol Oncol"},{"key":"3869_CR8","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","volume":"28","author":"A Malpica","year":"2004","unstructured":"Malpica, A. et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28, 496\u2013504 (2004).","journal-title":"Am J Surg Pathol"},{"key":"3869_CR9","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines: Ovarian cancer\/Fallopian tube cancer\/primary peritoneal cancer. Version 2. (2023)."},{"key":"3869_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/01.AOG.0000227787.24587.d1","volume":"108","author":"DM Gershenson","year":"2006","unstructured":"Gershenson, D. M. et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 108, 361\u2013368 (2006).","journal-title":"Obstet Gynecol"},{"key":"3869_CR11","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1136\/ijgc-2023-004610","volume":"33","author":"RN Grisham","year":"2023","unstructured":"Grisham, R. N. et al. Low-grade serous ovarian cancer: expert consensus report on the state of the science. Int J Gynecol Cancer 33, 1331\u20131344 (2023).","journal-title":"Int J Gynecol Cancer"},{"key":"3869_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","volume":"140","author":"JP Grabowski","year":"2016","unstructured":"Grabowski, J. P. et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecol Oncol 140, 457\u2013462 (2016).","journal-title":"Gynecol Oncol"},{"key":"3869_CR13","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","volume":"108","author":"KM Schmeler","year":"2008","unstructured":"Schmeler, K. M. et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 108, 510\u2013514 (2008).","journal-title":"Gynecol Oncol"},{"key":"3869_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/path.5545","volume":"253","author":"D Cheasley","year":"2021","unstructured":"Cheasley, D. et al. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. J Pathol 253, 41\u201354 (2021).","journal-title":"J Pathol"},{"key":"3869_CR15","doi-asserted-by":"publisher","first-page":"37663","DOI":"10.18632\/oncotarget.5438","volume":"6","author":"SM Hunter","year":"2015","unstructured":"Hunter, S. M. et al. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget 6, 37663\u201337677 (2015).","journal-title":"Oncotarget"},{"key":"3869_CR16","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/jnci\/95.6.484","volume":"95","author":"G Singer","year":"2003","unstructured":"Singer, G. et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95, 484\u2013486 (2003).","journal-title":"J Natl Cancer Inst"},{"key":"3869_CR17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","volume":"14","author":"J Farley","year":"2013","unstructured":"Farley, J. et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol 14, 134\u2013140 (2013).","journal-title":"Lancet Oncol"},{"key":"3869_CR18","doi-asserted-by":"publisher","first-page":"v897","DOI":"10.1093\/annonc\/mdz394.058","volume":"30","author":"DM Gershenson","year":"2019","unstructured":"Gershenson, D. M. et al. LBA61 - A randomized phase II\/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer. Annals of Oncology 30, v897\u2013v898 (2019).","journal-title":"Annals of Oncology"},{"key":"3869_CR19","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1200\/JCO.20.01164","volume":"38","author":"BJ Monk","year":"2020","unstructured":"Monk, B. J. et al. MILO\/ENGOT-ov11: Binimetinib Versus Physician\u2019s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. J Clin Oncol 38, 3753\u20133762 (2020).","journal-title":"J Clin Oncol"},{"key":"3869_CR20","doi-asserted-by":"crossref","unstructured":"Perera, N. & Hikkaduwa Koralege, R. S. in Encyclopedia of Toxicology (Fourth Edition) (ed Philip Wexler) 297\u2013301 (Academic Press, 2024).","DOI":"10.1016\/B978-0-12-824315-2.01035-6"},{"key":"3869_CR21","doi-asserted-by":"crossref","unstructured":"Hunter, S. et al. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget 6 (2015).","DOI":"10.18632\/oncotarget.5438"},{"key":"3869_CR22","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1158\/0008-5472.CAN-16-2224","volume":"77","author":"D Etemadmoghadam","year":"2017","unstructured":"Etemadmoghadam, D. et al. EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas. Cancer Res 77, 4268\u20134278 (2017).","journal-title":"Cancer Res"},{"key":"3869_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-019-0725-1","volume":"19","author":"ML Fernandez","year":"2019","unstructured":"Fernandez, M. L. et al. Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target. Cancer Cell Int 19, 10 (2019).","journal-title":"Cancer Cell Int"},{"key":"3869_CR24","first-page":"2235","volume":"6","author":"ML Fernandez","year":"2016","unstructured":"Fernandez, M. L. et al. Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines. Am J Cancer Res 6, 2235\u20132251 (2016).","journal-title":"Am J Cancer Res"},{"key":"3869_CR25","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1158\/0008-5472.CAN-20-2222","volume":"81","author":"R Shrestha","year":"2021","unstructured":"Shrestha, R. et al. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability. Cancer Res 81, 1681\u20131694 (2021).","journal-title":"Cancer Res"},{"key":"3869_CR26","doi-asserted-by":"publisher","first-page":"D1465","DOI":"10.1093\/nar\/gkad751","volume":"52","author":"Y Zhou","year":"2024","unstructured":"Zhou, Y. et al. TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res 52, D1465\u2013D1477 (2024).","journal-title":"Nucleic Acids Res"},{"key":"3869_CR27","doi-asserted-by":"publisher","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","volume":"52","author":"C Knox","year":"2024","unstructured":"Knox, C. et al. DrugBank 6.0: the DrugBank Knowledgebase for 2024. Nucleic Acids Res 52, D1265\u2013D1275 (2024).","journal-title":"Nucleic Acids Res"},{"key":"3869_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-021-04344-9","volume":"22","author":"DR Stirling","year":"2021","unstructured":"Stirling, D. R. et al. CellProfiler 4: improvements in speed, utility and usability. BMC Bioinformatics 22, 433 (2021).","journal-title":"BMC Bioinformatics"},{"key":"3869_CR29","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1093\/bioinformatics\/btv455","volume":"31","author":"JP Mpindi","year":"2015","unstructured":"Mpindi, J. P. et al. Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose-response data. Bioinformatics 31, 3815\u20133821 (2015).","journal-title":"Bioinformatics"},{"key":"3869_CR30","unstructured":"Pishas, K. I. et al BioStudies. https:\/\/identifiers.org\/biostudies:S-BIAD1069 (2024)."},{"key":"3869_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00379-8","volume":"7","author":"HJ Gray","year":"2023","unstructured":"Gray, H. J. et al. Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing. NPJ Precis Oncol 7, 45 (2023).","journal-title":"NPJ Precis Oncol"},{"key":"3869_CR32","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41416-022-02067-z","volume":"128","author":"A Murumagi","year":"2023","unstructured":"Murumagi, A. et al. Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma. Br J Cancer 128, 678\u2013690 (2023).","journal-title":"Br J Cancer"},{"key":"3869_CR33","doi-asserted-by":"publisher","first-page":"e183773","DOI":"10.1001\/jamaoncol.2018.3773","volume":"5","author":"G Falchook","year":"2019","unstructured":"Falchook, G. et al. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol 5, e183773 (2019).","journal-title":"JAMA Oncol"},{"key":"3869_CR34","doi-asserted-by":"crossref","unstructured":"Lauren P. et al. A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma. J Clin Oncol. 2022;40(suppl 16):5522.","DOI":"10.1200\/JCO.2022.40.16_suppl.5522"},{"key":"3869_CR35","doi-asserted-by":"crossref","unstructured":"Dall\u2019Acqua, A. et al. Inhibition of CDK4\/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives. Cancers (Basel) 13 (2021).","DOI":"10.3390\/cancers13123035"},{"key":"3869_CR36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ygyno.2024.03.029","volume":"186","author":"RL Hollis","year":"2024","unstructured":"Hollis, R. L. et al. High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma. Gynecol Oncol 186, 42\u201352 (2024).","journal-title":"Gynecol Oncol"},{"key":"3869_CR37","doi-asserted-by":"crossref","unstructured":"Da-Anoy, A. et al. Molecular Surrogate Subtypes of Ovarian and Peritoneal Low-grade Serous Carcinoma. Int J Gynecol Pathol (2024).","DOI":"10.1097\/PGP.0000000000001043"}],"container-title":["Scientific Data"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41597-024-03869-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41597-024-03869-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41597-024-03869-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T12:03:50Z","timestamp":1726747430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41597-024-03869-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3869"],"URL":"https:\/\/doi.org\/10.1038\/s41597-024-03869-x","relation":{},"ISSN":["2052-4463"],"issn-type":[{"value":"2052-4463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"assertion":[{"value":"18 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1024"}}